Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376456 | 0.89 | — | — | |
| SCHEMBL8374759 | 0.79 | ADH1B (0.47) | — | |
| SCHEMBL8374807 | 0.79 | ADH1B (0.47) | — | |
| SCHEMBL22157413 | 0.78 | TAS1R3 (0.32) | TAS1R3TAS1R1 | |
| SCHEMBL22157416 | 0.78 | TAS1R3 (0.32) | TAS1R3TAS1R1 | |
| SCHEMBL1678821 | 0.75 | — | — | |
| SCHEMBL22157365 | 0.74 | TAS1R3 (0.35) | TAS1R3TAS1R1 | |
| SCHEMBL8627522 | 0.74 | ADH1B (0.46) | TAS1R3TAS1R1 | |
| SCHEMBL3373342 | 0.74 | TAS1R3 (0.38) | TAS1R3TAS1R1 | |
| SCHEMBL543188 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110945438-B | Toner for developing electrostatic image | 日本瑞翁株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-108780288-B | Positively chargeable black toner | 日本瑞翁株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-20200166859-A1 | TONER FOR DEVELOPING ELECTROSTATIC IMAGES | ZEON CORPORATION (JP) | 2020-05-28 | — | — | US | disclosed |
| CN-110945438-A | Toner for developing electrostatic image | 日本瑞翁株式会社 | 2020-03-31 | — | — | CN | disclosed |
| US-20190041764-A1 | POSITIVELY-CHARGEABLE BLACK TONER | ZEON CORPORATION (JP) | 2019-02-07 | — | — | US | disclosed |
| US-8067140-B2 | reduced residual amount of a decomposed product of a polymerization initiator and an unreacted polymerizable monomer (mainly styrene), less odor produced upon fixing so as to avoid deteriorating surrounding environment, an excellent shelf stability at high temperature upon storing or anti-blocking | ZEON CORPORATION (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080182189-A1 | reduced residual amount of a decomposed product of a polymerization initiator and an unreacted polymerizable monomer (mainly styrene), less odor produced upon fixing so as to avoid deteriorating surrounding environment, an excellent shelf stability at high temperature upon storing or anti-blocking | ZEON CORPORATION (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1844052-A1 | THIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | Pharmacia & Upjohn Company LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079916-A1 | THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | TAS1R3 1059/4885TAS1R1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.